This HTML5 document contains 56 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00954/identifier/pharmgkb/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00954/identifier/wikipedia/
n9http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n13http://www.drugs.com/mtm/
n8http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/medicinal-product/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00954/identifier/kegg-drug/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n14http://www.rxlist.com/cgi/generic2/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00954/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n21http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/atc/
n10http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00954
rdf:type
n3:Drug
n3:description
Dirithromycin is a macrolide glycopeptide antibiotic. It is used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections.
n3:generalReferences
# Brogden RN, Peters DH: Dirithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1994 Oct;48(4):599-616. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7528132 # Wintermeyer SM, Abdel-Rahman SM, Nahata MC: Dirithromycin: a new macrolide. Ann Pharmacother. 1996 Oct;30(10):1141-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8893122 # Sides GD, Cerimele BJ, Black HR, Busch U, DeSante KA: Pharmacokinetics of dirithromycin. J Antimicrob Chemother. 1993 Mar;31 Suppl C:65-75. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8478313
n3:group
approved
n3:halfLife
The mean plasma half-life of erythromycylamine was estimated to be about 8 h (2 to 36 h), with a mean urinary terminal elimination half-life of about 44 h (16 to 65 h) in patients with normal renal function.
n3:indication
For the treatment of the following mild-to-moderate infections caused by susceptible strains of microorganisms: acute bacterial exacerbations of chronic bronchitis, secondary bacterial infection of acute bronchitis, community-acquired pneumonia, pharyngitis/tonsilitis, and uncomplicated skin and skin structure infections.
n3:manufacturer
n19:271B41EA-363D-11E5-9242-09173F13E4C5
owl:sameAs
n8:DB00954 n9:DB00954
dcterms:title
Dirithromycin
adms:identifier
n6:Dirithromycin n15:PA449368 n16:DB00954 n17:D03865
n3:mechanismOfAction
Dirithromycin prevents bacteria from growing, by interfering with their protein synthesis. Dirithromycin binds to the 50S subunit of the 70S bacterial ribosome, and thus inhibits the translocation of peptides. Dirithromycin has over 10 times higher affinity to the subunit 50S than erythromycin. In addition, dirithromycin binds simultaneously in to two domains of 23S RNA of the ribosomal subunit 50S, where older macrolides bind only in one. Dirithromycin can also inhibit the formation of ribosomal subunits 50S and 30S.
n3:toxicity
The toxic symptoms following an overdose of a macrolide antibiotic may include nausea, vomiting, epigastric distress, and diarrhea.
n3:proteinBinding
15 to 30% for erythromycylamine, the active compound.
n3:synthesisReference
# Counter FT, Ensminger PW, Preston DA, Wu CY, Greene JM, Felty-Duckworth AM, Paschal JW, Kirst HA: Synthesis and antimicrobial evaluation of dirithromycin (AS-E 136; LY237216), a new macrolide antibiotic derived from erythromycin. Antimicrob Agents Chemother. 1991 Jun;35(6):1116-26. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1929252
foaf:page
n13:dirithromycin.html n14:dirthromycin.htm n21:dyn1151.shtml
n3:IUPAC-Name
n4:271B41F1-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B41F7-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B41F6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B41F3-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B41F4-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B41F5-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B41EF-363D-11E5-9242-09173F13E4C5 n4:271B4207-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B41F0-363D-11E5-9242-09173F13E4C5 n4:271B41ED-363D-11E5-9242-09173F13E4C5 n4:271B4208-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B41EE-363D-11E5-9242-09173F13E4C5
n10:hasATCCode
n11:J01FA13
n3:H-Bond-Acceptor-Count
n4:271B41FD-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B41FE-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B41F8-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B41F9-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B41FB-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B41FA-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B41FC-363D-11E5-9242-09173F13E4C5
n3:absorption
Oral dirithromycin is rapidly absorbed, with an absolute bioavailability of approximately 10%. Dietary fat has little or no effect on the bioavailability of dirithromycin.
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
62013-04-1
n3:category
n3:containedIn
n20:271B41EB-363D-11E5-9242-09173F13E4C5 n20:271B41EC-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4203-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4205-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4206-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4202-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4201-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4204-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B41F2-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B41FF-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4200-363D-11E5-9242-09173F13E4C5